erlotinib has been researched along with alectinib in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (alectinib) | Trials (alectinib) | Recent Studies (post-2010) (alectinib) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 446 | 51 | 433 |
| Protein | Taxonomy | erlotinib (IC50) | alectinib (IC50) |
|---|---|---|---|
| Cyclin-G-associated kinase | Homo sapiens (human) | 0.01 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.0197 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 1.4 | |
| SRSF protein kinase 1 | Homo sapiens (human) | 0.195 | |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | 0.0682 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0748 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
1 review(s) available for erlotinib and alectinib
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for erlotinib and alectinib
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |